deltatrials
Terminated PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT02807181

SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma (SIRCCA)

Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma

Sponsor: Sirtex Medical

Conditions Intrahepatic Cholangiocarcinoma
Interventions Cisplatin-gemcitabine Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)
Updated 31 times since 2017 Last updated: Apr 23, 2025 Started: Feb 14, 2017 Primary completion: Apr 29, 2021 Completion: Apr 29, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow enrollment

Other terminated trials from Sirtex Medical

See all terminations from Sirtex Medical

Other Intrahepatic Cholangiocarcinoma trials with similar outcome

Browse all Intrahepatic Cholangiocarcinoma trials

This PHASE2/PHASE3 trial investigates Intrahepatic Cholangiocarcinoma and is currently terminated or withdrawn. Sirtex Medical leads this study, which shows 31 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Jun 2017 · 3 months · monthly snapshot~Jun 2017 – ~Jul 2017 · 30 days · monthly snapshot~Jul 2017 – ~Oct 2017 · 3 months · monthly snapshot~Oct 2017 – ~Nov 2017 · 31 days · monthly snapshot~Nov 2017 – ~May 2018 · 6 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Apr 2019 · 3 months · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jul 2019 · 2 months · monthly snapshot~Jul 2019 – ~Sep 2019 · 2 months · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Feb 2020 · 3 months · monthly snapshot~Feb 2020 – ~Dec 2020 · 10 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~May 2022 · 7 months · monthly snapshot~May 2022 – ~May 2023 · 12 months · monthly snapshot~May 2023 – ~Jul 2024 · 14 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshot~Jun 2025 – ~Sep 2025 · 3 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

31 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2/PHASE3

  2. Jun 2025 — Sep 2025 [monthly]

    Terminated PHASE2/PHASE3

    Status: Completed → Terminated

  3. Sep 2024 — Jun 2025 [monthly]

    Completed PHASE2/PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  5. May 2023 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

    Status: Active Not Recruiting → Completed

▶ Show 26 earlier versions

  1. May 2022 — May 2023 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  2. Oct 2021 — May 2022 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  3. Jan 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  4. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  5. Feb 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  6. Nov 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE2_PHASE3

    Status: Recruiting → Active Not Recruiting

  7. Sep 2019 — Nov 2019 [monthly]

    Recruiting PHASE2_PHASE3

  8. Jul 2019 — Sep 2019 [monthly]

    Recruiting PHASE2_PHASE3

  9. May 2019 — Jul 2019 [monthly]

    Recruiting PHASE2_PHASE3

  10. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE2_PHASE3

  11. Jan 2019 — Apr 2019 [monthly]

    Recruiting PHASE2_PHASE3

  12. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE2_PHASE3

  13. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE2_PHASE3

  14. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE2_PHASE3

  15. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE2_PHASE3

  16. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE2_PHASE3

  17. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE2_PHASE3

  18. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2_PHASE3

  19. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE2_PHASE3

  20. Nov 2017 — May 2018 [monthly]

    Recruiting PHASE2_PHASE3

    Phase: PHASE3 → PHASE2_PHASE3

  21. Oct 2017 — Nov 2017 [monthly]

    Recruiting PHASE3

  22. Jul 2017 — Oct 2017 [monthly]

    Recruiting PHASE3

    Phase: NA → PHASE3

  23. Jun 2017 — Jul 2017 [monthly]

    Recruiting NA

  24. Mar 2017 — Jun 2017 [monthly]

    Recruiting NA

  25. Feb 2017 — Mar 2017 [monthly]

    Recruiting NA

    Status: Not Yet Recruiting → Recruiting

  26. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting NA

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sirtex Medical
Data source: Sirtex Medical

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Barcelona, Spain , Brussels, Belgium , Clichy, France , Dijon, France , Grenoble, France , London, United Kingdom , Lyon, France , Manchester, United Kingdom , Marseille, France and 13 more locations